The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence : a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis

التفاصيل البيبلوغرافية
العنوان: The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence : a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
المؤلفون: Commons, RJ, Simpson, JA, Thriemer, K, Humphreys, GS, Abreha, T, Alemu, SG, Añez, A, Anstey, NM, Awab, GR, Baird, JK, Barber, BE, Borghini-Fuhrer, I, Chu, CS, D'Alessandro, U, Dahal, P, Daher, A, De Vries, PJ, Erhart, A, Gomes, MSM, Gonzalez-Ceron, L, Grigg, MJ, Heidari, A, Hwang, J, Kager, PA, Ketema, T, Khan, WA, Lacerda, MVG, Leslie, T, Ley, B, Lidia, K, Monteiro, WM, Nosten, F, Pereira, DB, Phan, GT, Phyo, AP, Rowland, M, Saravu, K, Sibley, CH, Siqueira, AM, Stepniewska, K, Sutanto, I, Taylor, WRJ, Thwaites, G, Tran, BQ, Tran, HT, Valecha, N, Vieira, JLF, Wangchuk, S, William, T, Woodrow, CJ, Zuluaga-Idarraga, L, Guerin, PJ, White, NJ, Price, RN
المساهمون: AII - Amsterdam institute for Infection and Immunity, Infectious diseases, AII - Infectious diseases
المصدر: The lancet infectious diseases
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Lancet infectious diseases, 18(9), 1025-1034. Lancet Publishing Group
LANCET INFECTIOUS DISEASES
سنة النشر: 2018
مصطلحات موضوعية: Adult, Male, Adolescent, Drug Resistance, Primaquine, Antimalarials, Young Adult, qv_258, Recurrence, parasitic diseases, Malaria, Vivax, qv_256, Humans, Child, Aged, Aged, 80 and over, Infant, Newborn, Infant, Chloroquine, Middle Aged, Child, Preschool, qx_135, Drug Therapy, Combination, Female, Human medicine, Plasmodium vivax
الوصف: BACKGROUND\ud Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports of treatment failure. We did a systematic review and meta-analysis to investigate the effect of chloroquine dose and the addition of primaquine on the risk of recurrent vivax malaria across different settings.\ud \ud METHODS\ud A systematic review done in MEDLINE, Web of Science, Embase, and Cochrane Database of Systematic Reviews identified P vivax clinical trials published between Jan 1, 2000, and March 22, 2017. Principal investigators were invited to share individual patient data, which were pooled using standardised methods. Cox regression analyses with random effects for study site were used to investigate the roles of chloroquine dose and primaquine use on rate of recurrence between day 7 and day 42 (primary outcome). The review protocol is registered in PROSPERO, number CRD42016053310.\ud \ud FINDINGS\ud Of 134 identified chloroquine studies, 37 studies (from 17 countries) and 5240 patients were included. 2990 patients were treated with chloroquine alone, of whom 1041 (34·8%) received a dose below the target 25 mg/kg. The risk of recurrence was 32·4% (95% CI 29·8-35·1) by day 42. After controlling for confounders, a 5 mg/kg higher chloroquine dose reduced the rate of recurrence overall (adjusted hazard ratio [AHR] 0·82, 95% CI 0·69-0·97; p=0·021) and in children younger than 5 years (0·59, 0·41-0·86; p=0·0058). Adding primaquine reduced the risk of recurrence to 4·9% (95% CI 3·1-7·7) by day 42, which is lower than with chloroquine alone (AHR 0·10, 0·05-0·17; p
وصف الملف: pdf; application/pdf
اللغة: English
تدمد: 1473-3099
4201-6053
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6285fd24b995109d72a07545c3cadd0cTest
https://hdl.handle.net/10067/1536920151162165141Test
حقوق: OPEN
رقم الانضمام: edsair.pmid.dedup....6285fd24b995109d72a07545c3cadd0c
قاعدة البيانات: OpenAIRE